Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 9/2015

01.08.2015 | Original Article

Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings

verfasst von: P. Payoux, J. Delrieu, A. Gallini, D. Adel, A. S. Salabert, A. Hitzel, C. Cantet, M. Tafani, D. De Verbizier, J. Darcourt, Ph. Fernandez, J. Monteil, I. Carrié, T. Voisin, S. Gillette-Guyonnet, M. Pontecorvo, B. Vellas, S. Andrieu

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Despite good to excellent inter-reader agreement in the evaluation of amyloid load on PET scans in subjects with Alzheimer's disease, some equivocal findings have been reported in the literature. We aimed to describe the clinical characteristics of subjects with equivocal PET images.

Methods

Nondemented subjects aged 70 years or more were enrolled from the MAPT trial. Cognitive and functional assessments were conducted at baseline, at 6 months, and annually for 3 years. During the follow-up period, 271 subjects had 18F-AV45 PET scans. Images were visually assessed by three observers and classified as positive, negative or equivocal (if one observer disagreed). After debate, equivocal images were reclassified as positive (EP+) or negative (EP−). Scans were also classified by semiautomated quantitative analysis using mean amyloid uptake of cortical regions. We evaluated agreement among the observers, and between visual and quantitative assessments using kappa coefficients, and compared the clinical characteristics of the subjects according to their PET results.

Results

In 158 subjects (58.30 %) the PET scan was negative for amyloid, in 77 (28.41 %) the scan was positive and in 36 (13.28 %) the scan was equivocal. Agreement among the three observers was excellent (kappa 0.80). Subjects with equivocal images were more frequently men (58 % vs. 37 %) and exhibited intermediate scores on cognitive and functional scales between those of subjects with positive and negative scans. Amyloid load differed between the EP− and negative groups and between the EP+ and positive groups after reclassification.

Conclusion

Equivocal amyloid PET images could represent a neuroimaging entity with intermediate amyloid load but without a specific neuropsychological pattern. Clinical follow-up to assess cognitive evolution in subjects with equivocal scans is needed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
8.
Zurück zum Zitat Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404–11. doi:10.1001/archneurol.2011.150.PubMedCrossRef Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404–11. doi:10.​1001/​archneurol.​2011.​150.PubMedCrossRef
12.
Zurück zum Zitat Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001;17:101–18.PubMedCrossRef Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001;17:101–18.PubMedCrossRef
14.
Zurück zum Zitat Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53:378–84. doi:10.2967/jnumed.111.090340.PubMedCrossRef Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53:378–84. doi:10.​2967/​jnumed.​111.​090340.PubMedCrossRef
15.
Zurück zum Zitat Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013;27:4–15. doi:10.1097/WAD.0b013e318279d02a.PubMedCrossRef Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013;27:4–15. doi:10.​1097/​WAD.​0b013e318279d02a​.PubMedCrossRef
16.
Zurück zum Zitat Carrie I, van Kan GA, Gillette-Guyonnet S, Andrieu S, Dartigues JF, Touchon J, et al. Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). J Nutr Health Aging. 2012;16:355–9.PubMedCrossRef Carrie I, van Kan GA, Gillette-Guyonnet S, Andrieu S, Dartigues JF, Touchon J, et al. Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). J Nutr Health Aging. 2012;16:355–9.PubMedCrossRef
17.
Zurück zum Zitat Gillette-Guyonnet S, Andrieu S, Dantoine T, Dartigues JF, Touchon J, Vellas B, et al. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease. Alzheimers Dement. 2009;5:114–21. doi:10.1016/j.jalz.2009.01.008.PubMedCrossRef Gillette-Guyonnet S, Andrieu S, Dantoine T, Dartigues JF, Touchon J, Vellas B, et al. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease. Alzheimers Dement. 2009;5:114–21. doi:10.​1016/​j.​jalz.​2009.​01.​008.PubMedCrossRef
18.
Zurück zum Zitat Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. MAPT study: a multidomain approach for preventing Alzheimer’s disease: design and baseline data. J Prevent Alzheimer’s Dis. 2014;1:13–22. Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. MAPT study: a multidomain approach for preventing Alzheimer’s disease: design and baseline data. J Prevent Alzheimer’s Dis. 2014;1:13–22.
19.
Zurück zum Zitat Nourhashemi F, Andrieu S, Gillette-Guyonnet S, Vellas B, Albarede JL, Grandjean H. Instrumental activities of daily living as a potential marker of frailty: a study of 7364 community-dwelling elderly women (the EPIDOS study). J Gerontol A Biol Sci Med Sci. 2001;56:M448–53.PubMedCrossRef Nourhashemi F, Andrieu S, Gillette-Guyonnet S, Vellas B, Albarede JL, Grandjean H. Instrumental activities of daily living as a potential marker of frailty: a study of 7364 community-dwelling elderly women (the EPIDOS study). J Gerontol A Biol Sci Med Sci. 2001;56:M448–53.PubMedCrossRef
20.
Zurück zum Zitat Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.PubMedCrossRef Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.PubMedCrossRef
21.
Zurück zum Zitat Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;38:900–3.PubMedCrossRef Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;38:900–3.PubMedCrossRef
22.
Zurück zum Zitat Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y. Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg. 1990;90:207–17.PubMed Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y. Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg. 1990;90:207–17.PubMed
23.
Zurück zum Zitat Wechsler D. Manual for the Wechsler adult intelligence scale – revised. New York: Psychological Corporation; 1981. Wechsler D. Manual for the Wechsler adult intelligence scale – revised. New York: Psychological Corporation; 1981.
24.
Zurück zum Zitat Reitan R. Validity of the trail making test as an indication of organic brain damage. Percept Mot Skills. 1958;8:271–6.CrossRef Reitan R. Validity of the trail making test as an indication of organic brain damage. Percept Mot Skills. 1958;8:271–6.CrossRef
25.
Zurück zum Zitat Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.PubMedCrossRef Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.PubMedCrossRef
26.
Zurück zum Zitat Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55:M221–31.PubMedCrossRef Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55:M221–31.PubMedCrossRef
27.
Zurück zum Zitat Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56.PubMedCrossRef Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56.PubMedCrossRef
28.
Zurück zum Zitat Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37–49.PubMedCrossRef Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37–49.PubMedCrossRef
29.
Zurück zum Zitat Klein G, Chiao P, Barakos J, Purcell D, Sampat M, Oh J, et al. Concordance of quantitative SUVr methods with visual assessment of florbetapir PET screening results. Alzheimers Dement. 2014;10(4 Suppl):P399CrossRef Klein G, Chiao P, Barakos J, Purcell D, Sampat M, Oh J, et al. Concordance of quantitative SUVr methods with visual assessment of florbetapir PET screening results. Alzheimers Dement. 2014;10(4 Suppl):P399CrossRef
30.
Zurück zum Zitat Nemmi F, Saint-Aubert L, Adel D, Salabert AS, Pariente J, Barbeau EJ, et al. Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer's disease patients and healthy subjects. Eur J Nucl Med Mol Imaging. 2014;41:1408–18. doi:10.1007/s00259-014-2728-4.PubMedCrossRef Nemmi F, Saint-Aubert L, Adel D, Salabert AS, Pariente J, Barbeau EJ, et al. Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer's disease patients and healthy subjects. Eur J Nucl Med Mol Imaging. 2014;41:1408–18. doi:10.​1007/​s00259-014-2728-4.PubMedCrossRef
31.
Zurück zum Zitat Chetelat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, et al. Relationship between memory performance and beta-amyloid deposition at different stages of Alzheimer's disease. Neurodegener Dis. 2012;10:141–4. doi:10.1159/000334295.PubMedCrossRef Chetelat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, et al. Relationship between memory performance and beta-amyloid deposition at different stages of Alzheimer's disease. Neurodegener Dis. 2012;10:141–4. doi:10.​1159/​000334295.PubMedCrossRef
32.
Zurück zum Zitat Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. doi:10.1016/S1474-4422(13)70044-9.PubMedCrossRef Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. doi:10.​1016/​S1474-4422(13)70044-9.PubMedCrossRef
33.
Zurück zum Zitat Saint-Aubert L, Nemmi F, Peran P, Barbeau EJ, Payoux P, Chollet F, et al. Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur J Nucl Med Mol Imaging. 2014;41:836–43. doi:10.1007/s00259-013-2656-8.PubMedCentralPubMedCrossRef Saint-Aubert L, Nemmi F, Peran P, Barbeau EJ, Payoux P, Chollet F, et al. Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur J Nucl Med Mol Imaging. 2014;41:836–43. doi:10.​1007/​s00259-013-2656-8.PubMedCentralPubMedCrossRef
Metadaten
Titel
Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings
verfasst von
P. Payoux
J. Delrieu
A. Gallini
D. Adel
A. S. Salabert
A. Hitzel
C. Cantet
M. Tafani
D. De Verbizier
J. Darcourt
Ph. Fernandez
J. Monteil
I. Carrié
T. Voisin
S. Gillette-Guyonnet
M. Pontecorvo
B. Vellas
S. Andrieu
Publikationsdatum
01.08.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2015
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3067-9

Weitere Artikel der Ausgabe 9/2015

European Journal of Nuclear Medicine and Molecular Imaging 9/2015 Zur Ausgabe